Kong Yaxian

Kong Yaxian

Professor

Doctoral Supervisor (Capital Medical University, Peking University Health Science Center) 

Academic Appointments

Standing Committee Member, Specialty Committee of Immunodeficiency Monitoring and Translational Research, China Association for Promotion of Health Science and Technology

Standing Committee Member, Zoonotic Tuberculosis Specialty Committee, Chinese Antituberculosis Association

Youth Committee Member, Hepatology Specialty Committee, Chinese Research Hospital Association

Standing Committee Member, Infectious Disease Specialty Committee, Beijing Research Association for Chronic Disease Control and Health Education

Committee Member, Health Testing and Laboratory Medicine Specialty Committee, Beijing Association of Preventive Medicine 

Academic Journal Appointment:

Young Editorial Board Member, Infectious Disease & Immunity

Research Focus:

Infection and Immunosenescence

Education and Work Experience

Sep. 1999 – Jul. 2004  Peking University Health Science Center, Clinical Medicine, Bachelor of Medicine

Sep. 2004 – Jul. 2009   Peking University Health Science Center, Stem Cell Center, Ph.D. in Cell Biology

Aug. 2009 – Oct. 2014   Institute for Infectious Diseases, Beijing Ditan Hospital Affiliated To Capital Medical University, Assistant Researcher

Dec. 2014 – Aug. 2015   The Pennsylvania State University (USA), Visiting Scholar

Nov. 2014 – Apr. 2019   Institute for Infectious Diseases,  Beijing Ditan Hospital Affiliated To Capital Medical University, Associate Researcher

Dec. 2017 – Dec. 2018   The Pennsylvania State University (USA), Visiting Scholar

Dec. 2019 – Present    Beijing Ditan Hospital Affiliated To Capital Medical University, Researcher

May 2023 – Present    Beijing Ditan Hospital Affiliated To Capital Medical University, Professor 

Selected Publications:

1. Zhang R#, Mu Y#, Zhang M#, Wu H, Xu Y, Zhao C, Liu Z, Lin L, Zhang W, Kong Y#, Chen Z*. Lactate Dehydrogenase/Albumin to Urea Ratio: A Novel Prognostic Indicator for Adverse Outcomes in Patients With Severe Fever With Thrombocytopenia Syndrome. J Med Virol. 2025 Jun;97(6):e70428.

2. Zhang L#, Zhao H#, Chen N#, Wang X#, Du J, Wang D, Liu Y, Wei Y, Zhang M, Deng M, Jiang M, Kong Y*. Increased frequency of Foxp3+CD8+T cells is associated with disease progression during HIV infection. AIDS. 2025 Jul 1;39(8):946-956.

3. Chen N#, Zhang L#, Wang X#, He Z, Wang D, Du J, Deng M, Zhang M, Jiang M, Wei Y, Zhao M, Liu Y, Wang X, Zhao H*, Kong Y*. Increased levels of Foxp3+CD4+NKT-like cells are associated with HIV disease progression. Clin Immunol. 2025 May 27;278:110533.

4. Wang X, Kong Y*. Advancing mechanistic understanding of post-acute sequelae of Ebola virus disease. Lancet Microbe. 2025 Apr 18:101139. doi: 10.1016/j.lanmic.

5. Wang X, Kong Y*. Crucial analysis of Nef-mediated MHC-I modulation in the maintenance of the HIV-1 reservoir. Lancet Microbe. 2025 Apr 1:101133. doi: 10.1016/j.lanmic.2025.101133.

6. Xie Y, Yan F, Liu X, Yu L, Yan H, Shang Z, Kong Y*, Yang Z*. FoxO1 as a Hub in Immunosenescence Induced by Hepatocellular Carcinoma and the Effect of Yangyin Fuzheng Jiedu Prescription. Drug Des Devel Ther. 2025 Mar 5;19:1543-1560.

Xie YQ, Yan FN, Yu LH, Yan HW, Kong YX*, Yang ZY*. Mechanism of Shashen-Maidong herb pair in treating hepatocellular carcinoma using network pharmacology and experimental validation. J Ethnopharmacol. 2025 Jan 30;337(Pt 3):118954.

7. Wang X, Wei Y, He Z, Wang D, Zhang L, Du J, Zhang M, Jiang M, Chen N, Deng M, Li B, Song C, Chen D, Liu H, Xiao J, Liang H, Zhao H, Kong Y*. CD70-induced Differentiation of Proinflammatory Th1/17/22/GM Lymphocytes Associated with Disease Progression and Immune Reconstitution During HIV Infection. Emerging Microbes & Infections. 2023 Dec;12(2):2271068.

8. Wang X#, Wang D#, Du J#, Wei Y, Song R, Wang B, Qiu S, Li B, Zhang L, Zeng Y, Zhao H, Kong Y*. High Levels of CD244 Rather Than CD160 Associate With CD8+ T-Cell Aging. Front Immunol. 2022 Mar 21;13:853522.

9. Kong Y#, Wang Y#, Wu X#, Han J, Li G, Hua M, Han K, Zhang H*, Li A*, Zeng H*. Storm of soluble immune checkpoints associated with disease severity of COVID-19. Signal Transduct Target Ther. 2020 Sep 7;5(1):192.

10. Kong Y#*, Han J#, Wu X#, Zeng H, Liu J*, Zhang H*. VEGF-D: a novel biomarker for detection of COVID-19 progression. Version 2. Crit Care. 2020 Jun 23;24(1):373.

11. Liu X, Li M, Wang X, Dang Z, Jiang Y, Wang X, Kong Y*, Yang Z*. PD-1+ TIGIT+ CD8+ T cells are associated with pathogenesis and progression of patients with hepatitis B virus-related hepatocellular carcinoma. Cancer Immunol Immunother. 2019 Dec; 68(12):2041-2054.

12. Kong Y, Jia B, Zhao C, Claxton DF, Sharma A, Annageldiyev C, Fotos JS, Zeng H, Paulson RF, Prabhu KS, Zheng H*. Downregulation of CD73 Associates with T cell Exhaustion in AML Patients. Journal of Hematology & Oncology. 2019 Apr 24;12(1):40.

13. Song Y, Wang B, Song R, Hao Y, Wang D, Li Y, Jiang Y, Xu L, Ma Y, Zheng H, Kong Y*, Zeng H*. T-cell Immunoglobulin and ITIM Domain Contributes to CD8+ T-cell Immunosenescence. Aging Cell.2018,17(2):12716.

14. Zhu L#, Kong Y #, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Palmisiano ND, Wang M, Jia B, Bayerl M, Schell TD, Hohl RJ, Zeng H, Zheng H. Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. J Hematol Oncol. 2017 Jun 19;10(1):124.

15. Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC, Rybka W, George MR, Zeng H*, Zheng H*. T-cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T cell Exhaustion and Poor Clinical Outcome in AML Patients. Clin Cancer Res. 2016 Jun 15;22(12):3057-66.

16. Kong Y, Li Y, Zhang W, Yuan S, Winkler R, Krohnert U, Han J, Lin T, Zhou Y, Miao P, Wang B, Zhang J, Yu Z, Zhang Y, Kosan C, Zeng H. Sepsis-Induced Thymic Atrophy is Associated with Defects in Early Lymphopoiesis. Stem Cells. 2016;34(12):2902-2915.

17. Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L, Zeng H, Schell TD, Zheng H*. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J. 2015 Jul 31;5:e330.

Talent Titles:

2025: Selected as one of the Most Outstanding Science and Technology Workers in Chaoyang District, Beijing2023: Selected for the “Dengfeng” Talent Program by the Beijing Municipal Hospital Administration

2023: Recognized as High-Level Public Health Technical Talent by the Beijing Municipal Health Commission

2021: Awarded the Beijing Distinguished Young Scientists Fund

2021: Selected for the “Phoenix Talent” Program of Beijing’s Chaoyang District

2016: Selected for the 2017 Beijing Nova Program

2016: Selected as a “Qingmiao” Talent by the Beijing Municipal Administration of Hospitals

Contact Information:

Email: kongyaxian@ccmu.edu.cn

Work Phone: 010-84322620